Annual Report - Glenmark

More documents

Recommendations

Info

Global. Research-focused. Integrated.
Objective To position the Company for growth and value creation in the global pharmaceutical industry <strong>Annual</strong> <strong>Report</strong> 2004-2005 3 Tenure The long-term and post-GATT [post-2005] scenario Driver A global market strategy, a strong research focus and an integrated business model for risk-mitigating delivery
Page 1 and 2: Glenmark Pharmaceuticals Limited An
Page 3: Consolidated Financial Highlights Y
Page 8 and 9: Global accounts for half the global
Page 10 and 11: Research-focused 6 In the post-GATT
Page 12 and 13: Integrated 8 Glenmark's business st
Page 14 and 15: Highlights, 2004-05 Consolidated re
Page 16 and 17: Interview with MD & CEO 12 Glenn Sa
Page 18 and 19: Our lead compound for Asthma and CO
Page 20 and 21: Business Divisional Analysis 16 Ind
Page 22 and 23: Domestic Formulations Performance H
Page 24 and 25: 20 accounted for almost 50 percent
Page 26 and 27: Active Pharmaceutical Ingredients 2
Page 28 and 29: Therapeutic segment contribution in
Page 30 and 31: International Formulations Performa
Page 32 and 33: 28 percent evinced a growth spurt i
Page 34 and 35: Research and Development 30 JANUARY
Page 36 and 37: 32 compounds are licensed to global
Page 38 and 39: Diabetes/Obesity Incidence Globally
Page 40 and 41: Global Management Team Name Glenn S
Page 42 and 43: 38 Revenues Glenmark's turnover for
Page 44 and 45: 40 Secured Loans Secured loans incr
Page 46 and 47: existing employees to keep them in
Page 48 and 49: 44 who are geared to respond to and
Page 50 and 51: Profit & loss Account (Rs. in ‘00
Page 52 and 53: PAT Margin Research and development
Page 54 and 55: Directors’ Report Your Directors
Page 56 and 57:
52 of the Company. On exercising th
Page 58 and 59:
Annexure to the Directors’ Report
Page 60 and 61:
v. The products launched and sold i
Page 62 and 63:
Disclosure pursuant to the provisio
Page 64 and 65:
Report on Corporate Governance Purs
Page 66 and 67:
B. Given below are the details of r
Page 68 and 69:
He is also a Director of following
Page 70 and 71:
Further resolutions with requisite
Page 72 and 73:
(All figures in Indian Rupees) Mont
Page 74 and 75:
) Risk as to fraudulent encashment
Page 76 and 77:
ANNEXURE TO AUDITORS’ REPORT Refe
Page 78 and 79:
Balance Sheet Rs. In (’000s) As a
Page 80 and 81:
Cash Flow Statement Rs. In (’000s
Page 82 and 83:
Schedules forming part of the Balan
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Schedules to the Profit & Loss Acco
Page 92 and 93:
Schedules forming part of the Finan
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
100 SECTION 212 STATEMENT PURSUANT
Page 106 and 107:
Consolidated Balance Sheet Rs. In (
Page 108 and 109:
Consolidated Cash Flow Statement Rs
Page 110 and 111:
Schedules forming part of the Conso
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
114 Notes to the Consolidated Accou
Page 120 and 121:
Notes to the Consolidated Accounts
Page 122 and 123:
118 Notes to the Consolidated Accou
Page 124:
14 13 12 43 19 71 49 10 5 20 62 3 3
show all

Annual Report - Glenmark

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?